Evodiamine improves congnitive abilities in SAMP8 and APPswe/PS1ΔE9 transgenic mouse models of Alzheimer's disease

Mattson MP . Pathways towards and away from Alzheimer's disease. Nature 2004; 430: 631–9.

Hardy J, Selkoe DJ . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353–6.

Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, van Gool WA, Hoozemans JJ . The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm 2006; 113: 1685–95.

Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216–23.

McGeer EG, McGeer PL . Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 741–9.

Heneka MT, O'Banion MK . Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007; 184: 69–91.

Rojo LE, Fernandez JA, Maccioni AA, Jimenez JM, Maccioni RB . Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 2008; 39: 1–16.

Hayden KM, Zandi PP, Khachaturian AS, Szekely CA, Fotuhi M, Norton MC, et al. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology 2007; 69: 275–82.

Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X, et al. miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res Bull 2009; 80: 268–73.

Butterfield DA, Poon HF . The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease. Exp Gerontol 2005; 40: 774–83.

Miyamoto M . Characteristics of age-related behavioral changes in senescence-accelerated mouse SAMP8 and SAMP10. Exp Gerontol 1997; 32: 139–48.

Flood JF, Morley JE . Learning and memory in the SAMP8 mouse. Neurosci Biobehav Rev 1998; 22: 1–20.

Kim HK, Kim M, Kim S, Kim M, Chung JH . Effects of green tea polyphenol on cognitive and acetylcholinesterase activities. Biosci Biotechnol Biochem 2004; 68: 1977–9.

Lu JH, Guo J, Yang WH . Effects of green tea polyphenol on the behaviour of Alzheimer' s disease like mice induced by D-galactose and Abeta25-35 . Zhong Yao Cai 2006; 29: 352–4.

Marambaud P, Zhao H, Davies P . Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005; 280: 37377–82.

Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE . Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 2009; 54: 111–8.

Sehirli O, Tozan A, Omurtag GZ, Cetinel S, Contuk G, Gedik N, et al. Protective effect of resveratrol against naphthalene-induced oxidative stress in mice. Ecotoxicol Environ Saf 2008; 71: 301–8.

Lee SH, Son JK, Jeong BS, Jeong TC, Chang HW, Lee ES, et al. Progress in the studies on rutaecarpine. Molecules 2008; 13: 272–300.

Wang L, Hu CP, Deng PY, Shen SS, Zhu HQ, Ding JS, et al. The protective effects of rutaecarpine on gastric mucosa injury in rats. Planta Med 2005; 71: 416–9.

Kobayashi Y, Nakano Y, Kizaki M, Hoshikuma K, Yokoo Y, Kamiya T . Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med 2001; 67: 628–33.

Cox MM, Tucker AM, Tang J, Talbot K, Richer DC, Yeh L, et al. Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background. Genes Brain Behav 2009; 8: 390–7.

Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, et al. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol 2009; 156: 982–93.

Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009; 34: 381–8.

Bussiere T, Bard F, Barbour R, Grajeda H, Guido T, Khan K, et al. Morphological characterization of thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol 2004; 165: 987–95.

Yu AS, Lin HD, Huang SC, Phelps ME, Wu HM . Quantification of cerebral glucose metabolic rate in mice using 18F-FDG and small-animal PET. J Nucl Med 2009; 50: 966–73.

Chow PL, Rannou FR, Chatziioannou AF . Attenuation correction for small animal PET tomographs. Phys Med Biol 2005; 50: 1837–50.

Blass JP . Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J Neurosci Res 2001; 66: 851–6.

Lin H, Tsai SC, Chen JJ, Chiao YC, Wang SW, Wang GJ, et al. Effects of evodiamine on the secretion of testosterone in rat testicular interstitial cells. Metabolism 1999; 48: 1532–5.

Yoshizumi M, Houchi H, Ishimura Y, Hirose M, Kitagawa T, Tsuchiya K, et al. Effect of evodiamine on catecholamine secretion from bovine adrenal medulla. J Med Invest 1997; 44: 79–82.

Chiou WF, Chou CJ, Shum AY, Chen CF . The vasorelaxant effect of evodiamine in rat isolated mesenteric arteries: mode of action. Eur J Pharmacol 1992; 215: 277–83.

Kobayashi Y . The nociceptive and anti-nociceptive effects of evodiamine from fruits of Evodia rutaecarpa in mice. Planta Med 2003; 69: 425–8.

King CL, Kong YC, Wong NS, Yeung HW, Fong HH, Sankawa U . Uterotonic effect of Evodia rutaecarpa alkaloids. J Nat Prod 1980; 43: 577–82.

Jiang J, Hu C . Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules 2009; 14: 1852–9.

Liu YN, Pan SL, Liao CH, Huang DY, Guh JH, Peng CY, et al. Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1alpha accumulation in RAW264.7. Shock 2009; 32: 263–9.

Ko HC, Wang YH, Liou KT, Chen CM, Chen CH, Wang WY, et al. Anti-inflammatory effects and mechanisms of the ethanol extract of Evodia rutaecarpa and its bioactive components on neutrophils and microglial cells. Eur J Pharmacol 2007; 555: 211–7.

Li Y, Liu L, Kang J, Sheng JG, Barger SW, Mrak RE, et al. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci 2000; 20: 149–55.

Vallieres L, Rivest S . Regulation of the genes encoding interleukin-6, its receptor, and gp130 in the rat brain in response to the immune activator lipopolysaccharide and the proinflammatory cytokine interleukin-1beta. J Neurochem 1997; 69: 1668–83.

Gruol DL, Nelson TE . Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 1997; 15: 307–39.

Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22–8.

Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383–421.

O'Banion MK, Miller JC, Chang JW, Kaplan MD, Coleman PD . Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J Neurochem 1996; 66: 2532–40.

Yamamoto K, Arakawa T, Ueda N, Yamamoto S . Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 1995; 270: 31315–20.

Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T . Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol 2009; 87: 181–94.